Figure 2
From: The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases
The difference between cumulative incidence curves of bleeding discontinuation during observational period among the patients treated with rivaroxaban or edoxaban. The red and blue lines indicate the patients treated with rivaroxaban and edoxaban, respectively.
